REFLEX:: a phase III trial to assess the effect of dosing frequency of interferon beta-1 a (Rebif®) in delaying conversion of patients with a clinically isolated syndrome to clinically definite multiple sclerosis

被引：0

|

作者：

Kappos, L.

Freedman, M.

De Stefano, N.

Labauge, R.

Comi, G.

Stubinski, B.

机构：

来源：

JOURNAL OF NEUROLOGY | 2007年 / 254卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

收藏

页码：103 / 103

页数：1

相关论文

共 50 条

[1] Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome
Freedman, Mark S.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2014, 7 (06) : 279 - 288
[2] Intramuscular interferon beta-1a delays conversion to clinically definite multiple sclerosis in patients with a clinically isolated syndrome: subgroup analyses based on new diagnostic criteria
Kinkel, R. P.
O'Connor, P. W.
Kremenchutzky, M.
MULTIPLE SCLEROSIS, 2006, 12 : S187 - S188
[3] AMETYST - Observational Phase IV Study Following the Influence of Intramuscularly Administered Interferon Beta-1a in Patients with Clinically Isolated Syndrome/Clinically Definite Multiple Sclerosis
Stourac, P.
Horakova, D.
Mavrov, I.
Turcani, P.
CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2014, 77 (04) : 465 - 472
[4] AMETYST - Results of an Observational Phase IV Clinical Study Evaluating the Effect of Intramuscular Interferon Beta-1a Therapy in Patients with Clinically Isolated Syndrome or Clinically Definite Multiple Sclerosis
Stourac, P.
Horakova, D.
Klimova, E.
Turcani, P.
CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2017, 80 (06) : 660 - 665
[5] A prospective study of the time to conversion to clinically definite multiple sclerosis in 172 Greek patients with clinically isolated syndrome
Koutsis, Georgios
Evangelopoulos, Maria Elephtheria
Karachalios, Georgios
Andreadou, Elisabeth
Mandellos, Dimitris
Vassilopoulos, Demetris
Sfagos, Constantinos
MULTIPLE SCLEROSIS, 2008, 14 : S72 - S72
[6] Efficacy of Two Dosing Frequencies of Subcutaneous Interferon Beta-1a on Risk of Conversion to Multiple Sclerosis in Patients with Clinically Isolated Syndrome: Results of a Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial (REFLEX)
Comi, Giancarlo
De Stefano, Nicola
Freedman, Mark S.
Kappos, Ludwig
Hennessy, Brian
Casset-Semanaz, Florence
Rocak, Sanda
Stubinski, Bettina
NEUROLOGY, 2011, 76 (09) : A612 - A612
[7] Treatment with glatiramer acetate delays conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome: subgroup analyses
Comi, Giancarlo
Carra, Adriana
Fazekas, Franz
Rieckmann, Peter
Bajenaru, O.
Hillert, Jan
Elovaara, Irina
Young, Carolyn
Wynn, Daniel
King, John
Lubetzki, Catherine
Hartung, Hans-Peter
Myhr, Kjell-Morten
Montalban, Xavier
Komoly, Samuel
Filippi, Massimo
MULTIPLE SCLEROSIS JOURNAL, 2008, 14 : S38 - S38
[8] Treatment with glatiramer acetate delays conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome suggestive of MS
Comi, G.
Filippi, M.
JOURNAL OF NEUROLOGY, 2008, 255 : 10 - 10
[9] Effect of early interferon beta-1a therapy on conversion to clinically definite multiple sclerosis in Iranian patients with a first demyelinating event
Pakdaman, H.
Fallah, A.
Pakdaman, R.
Sahraian, M. A.
Ghafarpour, M.
Gharaeghouzli, K.
JOURNAL OF NEUROLOGY, 2007, 254 : 166 - 166
[10] Effect of early interferon-beta1-a therapy on conversion to clinically definite multiple sclerosis in Iranian patients with a first demyelinating event
Pakdaman, H.
Fallah, A.
Pakdaman, R.
Shirani, A.
Sahraian, M.
MULTIPLE SCLEROSIS JOURNAL, 2006, 12 : S210 - S210

← 1 2 3 4 5 →